Headlines about Akari Therapeutics PLC (NASDAQ:AKTX) have been trending somewhat positive this week, according to Accern Sentiment. The research group identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Akari Therapeutics PLC earned a news impact score of 0.03 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 45.9204430789183 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Akari Therapeutics PLC (NASDAQ:AKTX) traded down $0.02 on Tuesday, hitting $4.46. The stock had a trading volume of 101,500 shares, compared to its average volume of 383,638. Akari Therapeutics PLC has a 52 week low of $3.18 and a 52 week high of $22.20.
Several research firms have recently issued reports on AKTX. Chardan Capital reiterated a “neutral” rating and set a $2.50 price target (down previously from $6.00) on shares of Akari Therapeutics PLC in a research note on Friday, August 11th. Zacks Investment Research upgraded Akari Therapeutics PLC from a “sell” rating to a “hold” rating in a research note on Monday. Canaccord Genuity reiterated a “buy” rating and set a $15.00 price target on shares of Akari Therapeutics PLC in a research note on Friday, September 22nd. William Blair upgraded Akari Therapeutics PLC from a “market perform” rating to an “outperform” rating in a research note on Friday, September 22nd. Finally, ValuEngine upgraded Akari Therapeutics PLC from a “strong sell” rating to a “sell” rating in a research note on Monday, September 11th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $8.00.
COPYRIGHT VIOLATION NOTICE: This report was originally published by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://transcriptdaily.com/2017/11/14/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-akari-therapeutics-plc-aktx-share-price.html.
Akari Therapeutics PLC Company Profile
Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.
Receive News & Ratings for Akari Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.